These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2883201)

  • 21. Insular cortex abnormalities in schizophrenia: Relationship to symptoms and typical neuroleptic exposure.
    Pressler M; Nopoulos P; Ho BC; Andreasen NC
    Biol Psychiatry; 2005 Feb; 57(4):394-8. PubMed ID: 15705355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Change in "overinclusive" thinking of schizophrenic patients is related to plasma phenothiazine concentration.
    Phillipson OT; Baker J; Williams M
    Adv Biochem Psychopharmacol; 1980; 24():591-7. PubMed ID: 6105805
    [No Abstract]   [Full Text] [Related]  

  • 27. The relationship between neuroleptic dosage and cognitive functioning in chronic schizophrenic patients.
    Hansen M; Paredes J; Koczapski A; Ledwidge B; Kogan C
    Clin Invest Med; 1987 Sep; 10(5):368-71. PubMed ID: 2890458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A validation study of forms A and B of the Whitaker Index of Schizophrenic Thinking.
    Evans RG; Dinning WD
    J Pers Assess; 1980 Aug; 44(4):416-9. PubMed ID: 7411382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Episodic and residual thought pathology in chronic schizophrenics: effect of neuroleptics.
    Spohn HE; Coyne L; Larson J; Mittleman F; Spray J; Hayes K
    Schizophr Bull; 1986; 12(3):394-407. PubMed ID: 2876514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ["Soteria Bern." Initial experiences with a new milieu therapy for acutely schizophrenic patients].
    Ciompi L; Bernasconi R
    Psychiatr Prax; 1986 Sep; 13(5):172-6. PubMed ID: 2878453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discrimination between and among schizophrenics and other pathologies using a Spanish version of the Whitaker Index of Schizophrenic Thinking.
    Godoy JF; Fernandez M; Muela JA; Roldan G; Catena A; Puente AE
    J Clin Psychol; 1994 Mar; 50(2):158-61. PubMed ID: 8014238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic-resistant schizophrenics.
    Murray JB
    J Psychol; 1989 Jan; 123(1):69-78. PubMed ID: 2564435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
    Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
    Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropsychological differentiation of chronic schizophrenia.
    Puente AE; Rodenbough J; Orrell TD
    Int J Neurosci; 1993 Oct; 72(3-4):193-200. PubMed ID: 7908012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overinclusive thinking and schizophrenia.
    Craig RJ
    J Pers Assess; 1971 Jun; 35(3):208-23. PubMed ID: 5097594
    [No Abstract]   [Full Text] [Related]  

  • 37. Standardization of the Whitaker Index of Schizophrenic Thinking (WIST) in a Mexican population: a multivariable study.
    Ornelas Bolado AL; Whitaker LC
    J Clin Psychol; 1990 Mar; 46(2):140-7. PubMed ID: 2324297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship of personality style to abstract thinking deficits in schizophrenia.
    Watson CG; Burke M; Plemel D
    J Clin Psychol; 1979 Apr; 35(2):247-9. PubMed ID: 457880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.
    Meltzer HY; Rabinowitz J; Lee MA; Cola PA; Ranjan R; Findling RL; Thompson PA
    Am J Psychiatry; 1997 Apr; 154(4):475-82. PubMed ID: 9090333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of schizophrenics with and without brain damage using the Whitaker Index of Schizophrenic Thinking.
    Puente AE; Sanders CH
    J Clin Psychol; 1981 Jul; 37(3):464-6. PubMed ID: 7263870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.